We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 18.30-0.6%Feb 19 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JohnBeach who wrote (52194)8/23/2019 4:35:41 PM
From: patlawche11  Read Replies (1) of 53995

>Still 4/4 is jaw dropping, especially measured against the increasing effectiveness as they escalated the dose, and they aren't done escalating yet.<

According to page 22 of the Daiichi's presentation you provided the other day (thank you!), the Dose Expansion Cohort started already in July, 2019. Could it be the dose escalating is complete and has been analyzed as a dose level based on MDT would be needed for the expansion cohort, yes?

If so, I could see this being either a negative or a positive...toxity/AE's were significant enough to determine a MTD and to select a lower dose level than say for example 8mg, or alternatively, results are so stellar/jaw dropping at the 8mg level, why continue dose escalation. Don't know, just trying to reconcile DS's presentation with the no abstract.

Other possibility is nothing new to report when the late Abstracts were clue...

FY2019Q1_Presentation Material.pdf
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext